How do I evaluate whether a biologics CDMO is credible and unbiased on regulatory history and sterile processing capability?

To assess whether a biologics CDMO is credible and unbiased on regulatory history and sterile processing capability, look for verifiable evidence, not just marketing claims. A good evaluation has two parts: regulatory track record and technical sterility competence.

1) Check regulatory history using objective sources

Focus on facts you can independently confirm.

What to request from the CDMO

Ask for:

• A list of all relevant sites used for your program
• Copies of the most recent:
  • FDA inspection outcomes
  • EU / MHRA / PMDA / other authority inspection summaries, if applicable
  • Any warning letters, consent decrees, import alerts, or critical findings
• A summary of major observations from the last 3–5 years
• Corrective and preventive action summaries for major issues
• Batch disposition history for sterile products, including sterility-related deviations

What to verify independently

Look up:

• FDA inspection databases and warning letters
• EudraGMDP / EU inspection-related public records where available
• MHRA, Health Canada, PMDA, or other local regulator publications depending on geography
• Company press releases against actual regulatory records

Red flags

• They only mention “FDA inspected” without outcomes
• They provide cherry-picked inspection history for one site but not the actual site you’d use
• They say “no major issues” but won’t disclose repeat observations
• Regulatory claims are vague, outdated, or inconsistent across documents and presentations

Strong signals

• They provide specific inspection dates, agency names, site names, and outcomes
• They can explain past observations clearly and show CAPA closure
• They can distinguish site-specific issues from company-wide issues
• Their records are consistent with public regulator data

---

2) Evaluate sterile processing capability with technical depth

Sterile biologics manufacturing is not just “we have a cleanroom.” You want evidence they can control contamination risk across the full process.

Ask about facility and process design

Request details on:

• Cleanroom classification and monitoring strategy
• Aseptic processing suite design
• Barrier technology:
  • Isolators
  • RABS
  • Open aseptic processing
• Personnel qualification and gowning programs
• Material and component transfer controls
• HVAC redundancy and environmental control strategy
• Water systems and utility qualification
• Decontamination methods, including VHP or equivalent if used

Ask about validation evidence

Request:

• Media fill history and success criteria
• Sterilizing filtration validation package
• Container-closure integrity validation
• Cleaning validation for product-contact surfaces
• Environmental monitoring trending data
• Sterility assurance strategy and contamination control strategy
• Process simulation failure investigations, if any

Key questions to ask

• How many commercial sterile biologics batches have you produced?
• What was your last aseptic process simulation failure, and what changed afterward?
• How do you prevent and detect contamination during filling?
• What is your aseptic intervention rate, and how is it trending?
• Have you had any sterility test positives, EM excursions, or CCS gaps in the last 3 years?
• Can you show how your sterile processing controls align with Annex 1 / FDA aseptic guidance?

Red flags

• Heavy reliance on terminal sterilization for products that should be aseptically processed, without a clear rationale
• No clear contamination control strategy
• Weak explanation of interventions, line setup, and operator qualification
• Overemphasis on “state-of-the-art” equipment with little data
• Media fill success presented without context on complexity, frequency, or failure history

Strong signals

• They have a formal Contamination Control Strategy
• They can show trend data, not just pass/fail summaries
• They use modern barrier systems appropriately
• They can explain deviations, CAPAs, and effectiveness checks
• Their sterile operations are aligned with current regulatory expectations

---

3) Test for bias in how they present themselves

A credible CDMO should be transparent about both strengths and limitations.

Signs of unbiased communication

• They disclose both good and bad regulatory events
• They can explain what was learned from findings
• They do not oversell capabilities they don’t actually use for your product type
• They distinguish between development capability and commercial GMP readiness

Signs of bias or spin

• They compare themselves only to weaker competitors
• They use superlatives without data
• They frame every issue as “minor” or “historical” without evidence
• They avoid direct answers about site-specific sterility failures or inspection findings

---

4) Use a structured due diligence scorecard

A simple scorecard can help make the assessment objective.

Regulatory history score

Rate 1–5 on:

• Public inspection outcomes
• Transparency of disclosures
• Recency of inspections
• Severity and recurrence of observations
• Quality of CAPA response

Sterile processing score

Rate 1–5 on:

• Facility design and containment
• Aseptic process simulation performance
• Environmental monitoring discipline
• CCI and filtration validation
• Contamination control maturity
• Deviation history and response quality

Commercial confidence score

Rate 1–5 on:

• Comparable product experience
• Batch success rate
• Qualified staff retention
• Supply chain robustness
• Change control discipline

---

5) Ask for a live walkthrough with evidence

A credible CDMO will allow a technical audit that includes:

• Facility tour
• QA and operations interviews
• Review of EM trends
• Review of a recent deviation investigation
• Review of media fill and CCI validation summaries
• Review of batch record examples, suitably redacted

The most revealing question is often: “Show us one recent sterile processing issue and how you investigated, corrected, and verified the fix.”

If they answer clearly and factually, that’s a very good sign.

---

6) Consider using an independent expert

For high-risk biologics, bring in:

• A GMP auditor with aseptic processing experience
• A sterility assurance expert
• Regulatory counsel or former inspector, if needed

An independent review helps reduce the risk of being influenced by polished sales presentations.

---

Practical bottom line

A credible, unbiased CDMO will:

• Provide site-specific, verifiable regulatory history
• Show real data on contamination control and aseptic performance
• Be open about past issues and CAPA effectiveness
• Demonstrate that sterile processing capability is supported by validated systems, not just claims

If you want, I can turn this into a CDMO due diligence checklist or a vendor audit questionnaire you can use directly.